
Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
Although more than half of U.S. pharmacy schools offering some education on end-of-life care, more needs to be done to train future R.Ph.s, according to a Texas Tech study.






